Barclays’s Theriva Biologics TOVX Stock Holding History

Barclays’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1	Buy	+3	New	+$1	﹤0.01%	5325
2026 Q1	–	Sell	-32,569	Closed	-$6.85K	–	5439
2025 Q4	$6.85K	Buy	+32,569	New	+$9.63K	﹤0.01%	4968
2024 Q4	–	Sell	-495	Closed	-$683	–	5477
2024 Q3	$683	Buy	+495	New	+$2.42K	﹤0.01%	5135
2021 Q4	–	Hold	0	–	–	–	4735
2021 Q3	–	Hold	0	–	–	–	5016
2021 Q2	–	Sell	-2	Closed	–	–	5079
2021 Q1	$0	Buy	+2	New	+$395	﹤0.01%	5189
2018 Q2	–	Hold	0	–	–	–	7283
2018 Q1	–	Hold	0	–	–	–	7332
2017 Q3	–	Sell	-13	Closed	-$62K	–	7047
2017 Q2	$62K	Buy	13 +11	+550%	+$54.8K	﹤0.01%	5229
2017 Q1	$11K	Buy	+2	New	+$14K	﹤0.01%	6055
2016 Q4	–	Hold	0	–	–	–	6494
2016 Q3	–	Hold	0	–	–	–	6447

Other funds holding TOVX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Barclays's TOVX Position: Q2 2026 in Review

Barclays opened a new position in Theriva Biologics (TOVX) in Q2 2026: 3 shares worth $1. The stake represents ﹤0.01% of the portfolio and ranks #5325 among its holdings. This is a return to the name: Barclays previously reported a position in TOVX as recently as Q4 2025.

Barclays first reported a position in TOVX in Q1 2017 and has held it in 6 quarters since. The position peaked at $62K in Q2 2017. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

Barclays held 3 shares of Theriva Biologics worth $1 as of Q2 2026.
Theriva Biologics was a new Barclays position in Q2 2026.
Theriva Biologics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5325 holding.
Barclays first reported a position in Theriva Biologics in Q1 2017 and has held it in 6 quarters since.
Barclays's Theriva Biologics position peaked at $62K in Q2 2017.
26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.